In vitro activity: CXCR2-IN-1 is a novel CNs (central nervous system) penetrant antagonist of CXCR2 with a pIC50 of 9.3. It was discovered by structure-activity relationship exploration of the historical biarylurea series. CXCR2-IN-1 displayed nanomolar potency, favorable PK profile, and good developability potentials. More importantly, it showed efficacy in a cuprizone-induced demyelination model with twice daily oral administration, thereby supporting CXCR2 to be a potential therapeutic target for the treatment of demyelinating diseases such as multiple sclerosis.
Kinase Assay: CXCR2-IN-1 is a novel CNs (central nervous system) penetrant antagonist of CXCR2 with a pIC50 of 9.3. CXCR2 plays an important role in the activation and recruitment of neutrophils to sites of inflammation. CXCR2-IN-1 shows favorable central nervous system penetration property (Br/Bl>0.45)
Cell Assay: |